• Our Commitment

    At Sobi, we want to contribute to a world where people with haemophilia live a full life, free from limitations.

    Find out more here
  • Our Heritage

    Our history of innovation in haemophilia is the foundation for our pioneering research today..

    Find out more here

We are Sobi Haemophilia

Sobi Haemophilia is part of Sobi, a specialty pharmaceutical company based in Stockholm, Sweden. We have a history of innovation in haemophilia that stretches back more than 50 years. Today, we continue to build on that history through a global partnership with Biogen Idec, an American biotechnology company, to develop new treatments for haemophilia. We have a fresh approach to partnering with the haemophilia community – people with haemophilia, their families, the healthcare professionals that care for them and the organisations that represent them – and look forward to sharing this with you.

By working with all members of the community, we can support the best possible, lifelong outcomes for every person with haemophilia – going beyond therapy to emphasise accurate evaluation, family support, long-term monitoring and data collection. We ask you to join in our dialogue and help us to connect with your needs and aspirations.

Geoffrey McDonough , MD, President and CEO of Sobi

About us

  • Global specialty pharmaceutical company
  • Focusing on rare diseases
  • Headquartered in Sweden
  • Nearly 600 employees worldwide
  • World-class research and manufacturing facilities
  • 50-year heritage in haemophilia

Sobi@ISTH2015

Sobi attended the ISTH 2015 conference in Toronto, Canada. The ISTH video blog was broadcasted daily in order to share learnings and bring part of the ISTH congress back to people who were not able to be in Toronto. Both haemophilia specialists and patient represenatives were interviewed.

Go to SobiPlay.com to view the blog.

Closing the haemophilia gap

Despite haemophilia being present throughout the world, the number of people identified and treated varies significantly, and the World Federation of Hemophilia has highlighted that, globally, only 25% of affected people have access to treatment.

Sobi and Biogen Idec want to be part of changing this.

About our humanitarian aid donation